Antitumor Activity of Celery Loaded Lipid PLGA-TPGS Nanoparticles in Glioblastoma
Glioblastoma (GBM) is a highly aggressive brain tumor characterized by high recurrence and poor prognosis. Natural compounds are good alternatives for treating glioblastoma and are less toxic than synthetic drugs. Apigenin (AGN) is an effective phytochemical with strong antioxidant and anticancer potential. However, due to its high lipophilicity, the therapeutic effect is limited. Therefore, apigenin lipid polymer hybrid nanoparticles (LPHyNPs) were prepared and characterized according to various parameters in this study. The mean particle size (234.100±23.320 nm), PDI (0.330±0.098), zeta potential (-5.403±0.650 mV), EE (54.99±4.13%), etc. Besides, Morphological analysis by SEM showed that the spherical NP had dark nuclei, indicating that the drug was embedded in the nucleus. In vitro release studies showed that continuous release of AGN from LPHyNPs significantly increased the suspension level of AGN (P<0.05). Cell proliferation and apoptosis experiments showed that LPHyNPs could significantly inhibit cell proliferation and promote cell apoptosis. Therefore, the LPHyNPs developed may be an effective therapeutic system for the management of GBM.
Shergalis A, Bankhead A, Luesakul U, et al. Current Challenges and Opportunities in Treating Glioblastoma. Pharmacol Rev. 2018; 3: 412-445.
Wang FY, Li WH. Preparation of apigenin nanostructured lipid carrier and its antitumor activity in vivo. Chinese patent Medicine. 2022; 007: 044.
Kim M, Jung J. The natural plant flavonoid apigenin is a strong antioxidant that effectively delays peripheral neurodegenerative processes. 2019; 4: 285-294.
Salehi B, Venditti A. The Therapeutic Potential of Apigenin. 2019; 6.
Imran M, Aslam Gondal T, Atif M, et al. Apigenin as an anticancer agent. 2020; 8: 1812-1828.
Xu R, Jiang C, Zhou L, et al. Fabrication of Stable Apigenin Nanosuspension with PEG 400 as Antisolvent for Enhancing the Solubility and Bioavailability. AAPS PharmSciTech. 2021; 1: 12.
Martinelli C, Pucci C. Nanostructured carriers as innovative tools for cancer diagnosis and therapy. 2019; 1: 011502.
Pucci C, Martinelli C, Ciofani G. Innovative approaches for cancer treatment: current perspectives and new challenges. Ecancermedicalscience. 2019; 961.
Yang Q, Zhou Y, Chen J, et al. Gene Therapy for Drug-Resistant Glioblastoma via Lipid-Polymer Hybrid Nanoparticles Combined with Focused Ultrasound. Int J Nanomedicine. 2021; 185-199.
Ishak RAH, Mostafa NM, Kamel AO. Stealth lipid polymer hybrid nanoparticles loaded with rutin for effective brain delivery - comparative study with the gold standard (Tween 80): optimization, characterization and biodistribution. Drug Deliv. 2017; 1: 1874-1890.
Arasoglu T, Derman S, Mansuroglu B. Comparative evaluation of antibacterial activity of caffeic acid phenethyl ester and PLGA nanoparticle formulation by different methods. Nanotechnology. 2016; 2: 025103.
Mahmoudi S, Ghorbani M, Sabzichi M, et al. Targeted hyaluronic acid-based lipid nanoparticle for apigenin delivery to induce Nrf2-dependent apoptosis in lung cancer cells. Journal of Drug Delivery Science & Technology. 2019; 268-276.
Li J, Liu X, Qiao Y, et al. Association Between Genetic Variant in the Promoter of Pri-miR-34b/c and Risk of Glioma. Front Oncol. 2018; 413.
Copyright (c) 2023 Jiajun Xu
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear
Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.